Abstract
Background
Epstein-Barr virus (EBV) is common in patients with Hodgkin's lymphoma (HL). It can lead to a loss of immune function, greatly increasing the HL risk. Clinical characteristics of RLH (reactive lymphoid hyperplasia) group and HL group were analyzed, and differences in cell morphology and CD30 expression were detected.
Results
There were no differences in clinical features between the RLH and HL groups. In terms of immune cell activity, compared with the RLH group, the HL group exhibited decreased proportions of CD4 + T cells and NK cells in lymphocytes, while the proportions of CD8 + T cells and CD19 cells were increased. The average expression rate of PD-1 was 51.14%, which indicated high expression. The expression of immune response products were significantly increased, and the expression of RIP2 was significantly decreased. The expression rates of IL-1β, IFN-α, INF-γ, TNF-α, IL-10, IL-6, IL-18, IL-17A, IL-8, IL-12P70, MCP-1, IL-23 and IL-33 were all increased in the patient group. WP5095, hsa04061, R-HSA-6785807, M196, hsa05321, and GO: 0032675 were significantly enriched pathways.
Conclusions
The changes of immune factors and inflammatory factors may also provide ideas for continuing to explore the biological treatment of EB positive Hodgkin lymphoma.